Literature DB >> 10720721

Amphetamine designer drugs - an overview and epidemiology.

A S Christophersen1.   

Abstract

The methylenedioxy-derivatives of amphetamine and methamphetamine represent the largest group of designer drugs. The most frequently used compounds are 3,4-methylenedioxy-methamphetamine (MDMA-ecstasy) and 3,4-methylenedioxy-amphetamine (MDA), first synthesised in 1910 (MDA) and 1914 (MDMA), respectively, to be used as an appetite suppressant. At the end of the 1960s, non-medical (recreational) use appeared in the USA, and in the middle of the 1980s in Europe. In Norway, MDMA and related compounds have been detected in forensic samples since the early 1990s. In order to bypass the legal regulations and to produce more potent substances, a number of related compounds have been synthesised, including derivatives with one or more substituents (methoxy, methyl, halogen or sulphur), attached at different positions to the phenylring of amphetamine or methamphetamine. A report from 1998 shows that 0.5-3% of the adult European population, mainly young people, has used ecstasy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720721     DOI: 10.1016/s0378-4274(99)00205-2

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  12 in total

Review 1.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

2.  Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy").

Authors:  Boris B Quednow; Kai-Uwe Kühn; Christian Hoppe; Jens Westheide; Wolfgang Maier; Irene Daum; Michael Wagner
Journal:  Psychopharmacology (Berl)       Date:  2006-01-20       Impact factor: 4.530

3.  A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.

Authors:  D N Bateman; P R McElhatton; D Dickinson; C Wren; J N S Matthews; M O'Keeffe; S H L Thomas
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

4.  What's in a label? Ecstasy sellers' perceptions of pill brands.

Authors:  Micheline Duterte; Camille Jacinto; Paloma Sales; Sheigla Murphy
Journal:  J Psychoactive Drugs       Date:  2009-03

Review 5.  Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner.

Authors:  Nalini Vadivelu; Harman Singh-Gill; Gopal Kodumudi; Aaron Joshua Kaye; Richard D Urman; Alan David Kaye
Journal:  Ochsner J       Date:  2014

6.  Ecstasy-induced recurrent toxic hepatitis in a young adult.

Authors:  Ozlem Guneysel; Ozge Ecmel Onur; Haldun Akoglu; Arzu Denizbasi
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

7.  Amphetamine-type stimulants (ATS) drug classification using shallow one-dimensional convolutional neural network.

Authors:  Norfadzlia Mohd Yusof; Azah Kamilah Muda; Satrya Fajri Pratama; Ramon Carbo-Dorca
Journal:  Mol Divers       Date:  2021-08-02       Impact factor: 2.943

8.  Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Authors:  Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

9.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

10.  Vaccine-driven pharmacodynamic dissection and mitigation of fenethylline psychoactivity.

Authors:  Cody J Wenthur; Bin Zhou; Kim D Janda
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.